AI-assisted, human-published
08/11/2026 /Funding Events
Vaderis Therapeutics Secures $152M Funding and Commences Phase 3 Clinical Study for Rare Vascular Diseases Treatment
Vaderis Therapeutics completes private $152M Series B financing and launches global Phase 3 clinical study for engasertib in patients with hereditary hemorrhagic telangiectasia (HHT).
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com